Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study.
Premal H ThakerTirza Areli Calderón BoyleSara BurnsJonathan LimJohn HartmanLinda V KalilaniJeanne M SchilderJean A HurteauAmanda K GolembeskyPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
In this real-world study of patients receiving niraparib-bevacizumab first-line maintenance, the majority of whom had HRp/HR status unknown, the median time to next treatment was consistent with observed progression-free survival in patients with similar HR status in the OVARIO study.